PH12015502462A1 - Imidazo-triazine derivatives as pde10 inhibitors - Google Patents

Imidazo-triazine derivatives as pde10 inhibitors

Info

Publication number
PH12015502462A1
PH12015502462A1 PH12015502462A PH12015502462A PH12015502462A1 PH 12015502462 A1 PH12015502462 A1 PH 12015502462A1 PH 12015502462 A PH12015502462 A PH 12015502462A PH 12015502462 A PH12015502462 A PH 12015502462A PH 12015502462 A1 PH12015502462 A1 PH 12015502462A1
Authority
PH
Philippines
Prior art keywords
imidazo
triazine derivatives
pde10 inhibitors
pde10
inhibitors
Prior art date
Application number
PH12015502462A
Other languages
English (en)
Inventor
Chappie Thomas Allen
Helal Christopher John
Kormos Bethany Lyn
Tuttle Jamison Bryce
Verhoest Patrick Robert
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PH12015502462A1 publication Critical patent/PH12015502462A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PH12015502462A 2013-05-02 2015-10-23 Imidazo-triazine derivatives as pde10 inhibitors PH12015502462A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361818650P 2013-05-02 2013-05-02
PCT/IB2014/060945 WO2014177977A1 (en) 2013-05-02 2014-04-23 Imidazo-triazine derivatives as pde10 inhibitors

Publications (1)

Publication Number Publication Date
PH12015502462A1 true PH12015502462A1 (en) 2016-02-22

Family

ID=50841902

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12015502462A PH12015502462A1 (en) 2013-05-02 2015-10-23 Imidazo-triazine derivatives as pde10 inhibitors

Country Status (33)

Country Link
US (3) US8933224B2 (https=)
EP (1) EP2991989B1 (https=)
JP (1) JP6263606B2 (https=)
KR (1) KR101770905B1 (https=)
CN (1) CN105164134B (https=)
AP (1) AP2015008843A0 (https=)
AR (1) AR096161A1 (https=)
AU (1) AU2014261070A1 (https=)
BR (1) BR112015027760A8 (https=)
CA (1) CA2910759C (https=)
CL (1) CL2015003037A1 (https=)
CR (1) CR20150591A (https=)
CU (1) CU20150144A7 (https=)
DK (1) DK2991989T3 (https=)
DO (1) DOP2015000271A (https=)
EA (1) EA027936B1 (https=)
EC (1) ECSP15050110A (https=)
ES (1) ES2637816T3 (https=)
GE (1) GEP201706675B (https=)
MA (1) MA38559B1 (https=)
MD (1) MD20150103A2 (https=)
MX (1) MX2015015163A (https=)
NI (1) NI201500157A (https=)
NZ (1) NZ712949A (https=)
PE (1) PE20151940A1 (https=)
PH (1) PH12015502462A1 (https=)
SG (1) SG11201508201VA (https=)
TN (1) TN2015000490A1 (https=)
TW (1) TWI508966B (https=)
UA (1) UA111696C2 (https=)
UY (1) UY35547A (https=)
WO (1) WO2014177977A1 (https=)
ZA (1) ZA201508968B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA027936B1 (ru) * 2013-05-02 2017-09-29 Пфайзер Инк. Производные имидазотриазина в качестве ингибиторов фосфодиэстеразы 10 (pde10)
CR20190119A (es) 2016-09-09 2019-06-03 Novartis Ag Compuestos y composiciones como inhibidores de los receptores endosomales tipo peaje
CN112839648B (zh) 2018-06-07 2025-04-04 达萨玛治疗公司 Sarm1抑制剂
EP3897670A4 (en) 2018-12-19 2022-09-07 Disarm Therapeutics, Inc. MRSA1 INHIBITORS IN COMBINATION WITH NEUROPROTECTIVE AGENTS
CA3155209A1 (en) * 2019-10-21 2021-04-29 Chan Mi Joung Use of imidazopyrimidine or imidazotriazine compounds for prevention, alleviation, or treatment of cognitive disorders, or for improving cognitive function
US12516064B2 (en) * 2022-02-02 2026-01-06 SpringWorks Therapeutics Inc. Tetrahydropyridopyrimidines and related analogs for inhibiting YAP/TAZ-TEAD

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010007867A1 (en) 1999-12-13 2001-07-12 Yuhpyng L. Chen Substituted 6,5-hetero-bicyclic derivatives
DE10130167A1 (de) 2001-06-22 2003-01-02 Bayer Ag Imidazotriazine
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
DE10230604A1 (de) 2002-07-08 2004-01-29 Bayer Ag Heterocyclisch substituierte Imidazotriazine
EP1651251A4 (en) 2003-07-31 2008-06-18 Bayer Pharmaceuticals Corp METHOD FOR THE TREATMENT OF DIABETES AND RELATED DISEASES USING PDE 10A INHIBITORS
JP4559749B2 (ja) * 2004-02-16 2010-10-13 あすか製薬株式会社 ピペラジニルピリジン誘導体
EP1595881A1 (en) 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
US20070167426A1 (en) 2004-06-02 2007-07-19 Schering Corporation Compounds for the treatment of inflammatory disorders and microbial diseases
TW200716102A (en) 2005-06-01 2007-05-01 Wyeth Corp Bicyclic 6-alkylidene-penems as class-D β -lactamases inhibitors
US20080051419A1 (en) 2006-07-26 2008-02-28 Pfizer Inc. Amine derivatives useful as anticancer agents
JP5274256B2 (ja) 2006-09-26 2013-08-28 株式会社カネカ 光学活性β−ヒドロキシ−α−アミノカルボン酸エステルの製造方法
WO2008057402A2 (en) 2006-11-02 2008-05-15 Cytovia, Inc. N-aryl-isoxazolopyrimidin-4-amines and related compounds as activators of caspases and inducers of apoptosis and the use thereof
EP2203171A2 (en) 2007-08-21 2010-07-07 Merck Sharp & Dohme Corp. Cb2 receptor ligands for the treatment of pain
DE102007059723A1 (de) 2007-12-12 2009-06-18 Siemens Medical Instruments Pte. Ltd. Hörvorrichtung mit Batterieklappenmodul
TWI431010B (zh) 2007-12-19 2014-03-21 Lilly Co Eli 礦皮質素受體拮抗劑及使用方法
CA2716856C (en) 2008-03-20 2013-02-19 Amgen Inc. Aurora kinase modulators and method of use
KR101774035B1 (ko) * 2009-10-30 2017-09-01 얀센 파마슈티카 엔.브이. 이미다조[1,2―b]피리다진 유도체 및 PDE10 저해제로서의 그의 용도
US9073927B2 (en) 2010-01-22 2015-07-07 Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii Inhibitors of PI3 kinase
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
TW201200518A (en) 2010-03-10 2012-01-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
WO2011141713A1 (en) 2010-05-13 2011-11-17 Centro Nacional De Investigaciones Oncologicas (Cnio) New bicyclic compounds as pi3-k and mtor inhibitors
MX2012013824A (es) 2010-05-28 2013-03-12 Biocryst Pharm Inc Compuestos heterociclicos como inhibidores de cinasa janus.
WO2011157793A1 (en) 2010-06-17 2011-12-22 Novartis Ag Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
KR101548443B1 (ko) * 2011-02-23 2015-08-28 화이자 인코포레이티드 신경 장애의 치료를 위한 이미다조[5,1-f][1,2,4]트라이아진
EA027936B1 (ru) * 2013-05-02 2017-09-29 Пфайзер Инк. Производные имидазотриазина в качестве ингибиторов фосфодиэстеразы 10 (pde10)

Also Published As

Publication number Publication date
US20150080401A1 (en) 2015-03-19
EA201591819A1 (ru) 2016-05-31
EP2991989A1 (en) 2016-03-09
BR112015027760A8 (pt) 2018-05-08
JP6263606B2 (ja) 2018-01-17
DOP2015000271A (es) 2016-02-29
GEP201706675B (en) 2017-05-25
NI201500157A (es) 2015-11-30
EP2991989B1 (en) 2017-06-28
MX2015015163A (es) 2016-02-22
CL2015003037A1 (es) 2016-04-22
MA38559B1 (fr) 2018-04-30
AU2014261070A1 (en) 2015-10-29
CN105164134A (zh) 2015-12-16
US9145427B2 (en) 2015-09-29
KR101770905B1 (ko) 2017-08-23
ECSP15050110A (es) 2017-08-31
TN2015000490A1 (fr) 2017-04-06
AR096161A1 (es) 2015-12-09
PE20151940A1 (es) 2016-01-21
NZ712949A (en) 2017-04-28
TWI508966B (zh) 2015-11-21
CA2910759C (en) 2018-01-16
WO2014177977A1 (en) 2014-11-06
ZA201508968B (en) 2017-11-29
JP2016517877A (ja) 2016-06-20
US8933224B2 (en) 2015-01-13
DK2991989T3 (en) 2017-07-31
EA027936B1 (ru) 2017-09-29
AP2015008843A0 (en) 2015-11-30
UA111696C2 (uk) 2016-05-25
MD20150103A2 (ro) 2016-02-29
CR20150591A (es) 2016-01-04
US20150353579A1 (en) 2015-12-10
US9296761B2 (en) 2016-03-29
CU20150144A7 (es) 2016-04-25
SG11201508201VA (en) 2015-11-27
HK1213885A1 (zh) 2016-07-15
CN105164134B (zh) 2017-09-22
KR20160003234A (ko) 2016-01-08
US20140329820A1 (en) 2014-11-06
UY35547A (es) 2014-11-28
TW201506027A (zh) 2015-02-16
ES2637816T3 (es) 2017-10-17
CA2910759A1 (en) 2014-11-06

Similar Documents

Publication Publication Date Title
PH12016500676A1 (en) Pyrimidine fgfr4 inhibitors
PH12017500408A1 (en) Heteroaryl compunds as btk inhibitors and uses thereof
CR20150509A (es) Derivados de naftiridina utiles como antagonistas de la alfa-v-beta-6 integrina
PH12015500263A1 (en) New bicyclic derivatives
MX341456B (es) Amino-quinolinas como inhibidores de cinasa.
MX2014014531A (es) Derivados de aminoquinazolina y piridopirimidina.
CR20150470A (es) Derivados de triazolona de piridinilo y piridinilo fusionado
UA116395C2 (uk) ПОХІДНІ ТРИАЗОЛ[4,5-b]ПІРИМІДИНУ
PH12015501843A1 (en) Novel pyrazol derivatives
PH12015500345A1 (en) Amino-quinolines as kinase inhibitors
JO3318B1 (ar) مثبطات bace
EA201590561A1 (ru) Пролекарства аминохиназолинового ингибитора киназы
PH12015502462A1 (en) Imidazo-triazine derivatives as pde10 inhibitors
MY180050A (en) Novel purine derivatives
PH12015501175A1 (en) Substituted pyridopyrazines as syk inhibitors
MX2015013365A (es) Derivados de urea y su uso como inhibidores de proteina de union de acidos grasos (puag).
MX373636B (es) Compuestos de azetidiniloxifenilpirrolidina.
MX2015013374A (es) Derivados de urea y su uso como inhibidores de proteina de uniuon a acidos grasos (puag).
MX2015016766A (es) Nuevos derivados de tetrazolona.
MX2015011005A (es) Derivados de dihidorquinolin-2-ona para usarse como inhibidores de aldoesterona sintasa.
MX2016006807A (es) Derivados de imidazol.
MX2015009377A (es) Compuestos radiomarcados.
JO3298B1 (ar) مشتقات جليكوبيرانوسيل-مستبدل و اندول-يوريا و استعمالاتهم كمثبطات sglt
IN2012DE00110A (https=)
MX2016002762A (es) Derivados de fenil-dihidropiridina como inhibidores de aldosterona sintasa.